This paper is in the following e-collection/theme issue:

COVID-19 Vaccination (140) JMIR Theme Issue: COVID-19 Special Issue (2439) Infectious Diseases (non-STD/STI) (1555) Outbreak and Pandemic Preparedness and Management (1714) Theme Issue: Novel Coronavirus (COVID-19) Outbreak Rapid Reports (1513) Vaccination and Immunization in the Digital Age (365) Hygiene and Infection Prevention (310)

Published on in Vol 8, No 11 (2022): November

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/38898, first published .
The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data

The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data

The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data

Authors of this article:

Meghana Kshirsagar1 Author Orcid Image ;   Md Nasir1 Author Orcid Image ;   Sumit Mukherjee2 Author Orcid Image ;   Nicholas Becker1, 3 Author Orcid Image ;   Rahul Dodhia1 Author Orcid Image ;   William B Weeks1 Author Orcid Image ;   Juan Lavista Ferres1 Author Orcid Image ;   Barbra Richardson4 Author Orcid Image
Article Authors Cited by (5) Tweetations (6) Metrics

Meghana Kshirsagar   1 , BS, MS, PhD ;   Md Nasir   1 , BS, PhD ;   Sumit Mukherjee   2 , BS, PhD ;   Nicholas Becker   1, 3 , BS, MS ;   Rahul Dodhia   1 , BS, PhD ;   William B Weeks   1 , MD, PhD ;   Juan Lavista Ferres   1 , BS, MS ;   Barbra Richardson   4 , BS, MS, PhD

1 Microsoft, Redmond, WA, United States

2 Insitro Inc, South San Francisco, CA, United States

3 Paul G Allen School of Computer Science & Engineering, University of Washington, Seattle, WA, United States

4 Department of Biostatistics and Global Health, University of Washington, Seattle, WA, United States

Corresponding Author: